UK Guidelines on Pancreas and Islet Transplantation

UK Guidelines on Pancreas and Islet Transplantation
British Transplantation Society September 2019

• These guidelines cover solid organ pancreas transplantation and allogeneic islets of Langerhans transplantation, but exclude islet autotransplantation. Includes a Summary Table of Outcome Measures in simultaneous pancreas-kidney transplantation.

Hepatitis C in England 2019

Hepatitis C in England, 2019 report: Working to eliminate hepatitis C as a major public health threat
PHE 9 April 2019

• The report summarises the scale of the Hepatitis C virus (HCV)  problem in 2017 in England, to help support focused action to meet the commitment to reduce the incidence of chronic HCV infection by 80% and HCV mortality by 65% by 2030 at the latest.
• The Hepatitis C patient registry and treatment outcome system was developed by Arden GEM CSU.

Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation

Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation [IPG636]
NICE Interventional procedures guidance, January 2019

• Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of livers for transplantation in people of all ages. This involves using a machine to give an oxygenated solution to the donor liver until it is transplanted.

Hepatitis C treatment monitor, patient re-engagement

Hepatitis C: guidance, data and analysis
Public Health England updated November 2018

• Guidance on the characteristics, diagnosis, management and epidemiology of hepatitis C (Hep C, HCV). Two new documents have been added to the collection: 
• Hepatitis C treatment monitoring in England
• Hepatitis C: patient re-engagement exercise

Liver disease profiles: November 2018 update

Liver disease profiles: November 2018 update
PHE November 6 2018

• Mortality data for 2015-17 for Alcohol-related liver disease, hepatitis B, hepatitis C and Non-alcoholic fatty liver disease.
• For trends see the Liver disease profiles: short statistical commentary

Direct tests for liver disease

What is the most accurate and cost-effective direct test (ELF test™, hyaluronic acid, P3NP, Fibroscan® or ARFI elastography) for detecting and staging liver fibrosis and/or cirrhosis in patients with diagnosed or suspected non-alcoholic fatty liver disease, alcohol-related liver disease, or viral hepatitis?
Healthcare Improvement Scotland, SHTG team, 23 July 2018

• Performance of the ELF test™, hyaluronic acid, P3NP , Fibroscan® and ARFI elastography for the detection and staging of liver fibrosis and cirrhosis in a secondary or tertiary care setting.
• Advice statement available here.

‘My Liver’ – liver cancer app

‘My Liver’ – Educating & Supporting Patients with Liver Cancer
26 April 2018

• ‘My Liver’ app is a dedicated information guide designed to offer information and support for those patients (and families) who are diagnosed with liver cancer, helping them through each stage in their journey. The free to download app covers initial referral to treatment, how to manage symptoms and where to find further help and support. 
• My Liver’ is the second in the series of planned apps designed by the team from Leicester Hepato-Pancreato-Biliary (HPB) Unit & digital design agency AGF Studio, the first being ‘My Pancreas’ which was launched worldwide in April 2017.

Liver disease profiles include detection rate for hepatitis C

Liver disease profiles: April 2018 update
PHE 4 April 2018

• A new indicator for the detection rate of confirmed chronic hepatitis C has been added to the profiles.
• The highest rate is given as 222.1 per 100,000 in Hammersmith & Fulham.